157 results on '"Chaudhry, Basit"'
Search Results
2. Hypersensitivity to BKCa channel opening in persistent post-traumatic headache
- Author
-
Al-Khazali, Haidar M., Christensen, Rune H., Dodick, David W., Chaudhry, Basit Ali, Melchior, Anna G., Burstein, Rami, and Ashina, Håkan
- Published
- 2024
- Full Text
- View/download PDF
3. Effects of PDE-3 inhibition in persistent post-traumatic headache: evidence of cAMP-dependent signaling
- Author
-
Al-Khazali, Haidar M., Christensen, Rune H., Chaudhry, Basit Ali, Melchior, Anna G., Ashina, Messoud, Burstein, Rami, and Ashina, Håkan
- Published
- 2024
- Full Text
- View/download PDF
4. The Impact of Biosimilar Use on Total Cost of Care and Provider Financial Performance in the Medicare Oncology Care Model: A Population-Based Simulation Study
- Author
-
Yang, Jingyan, Chaudhry, Basit I., Yue, Andrew T., Roth, Joshua A., Kelton, John M., Shelbaya, Ahmed, Tran, Lisa, and Li, Meng
- Published
- 2024
- Full Text
- View/download PDF
5. Menstrual migraine is caused by estrogen withdrawal: revisiting the evidence
- Author
-
Raffaelli, Bianca, Do, Thien Phu, Chaudhry, Basit Ali, Ashina, Messoud, Amin, Faisal Mohammad, and Ashina, Håkan
- Published
- 2023
- Full Text
- View/download PDF
6. CGRP-induced migraine-like headache in persistent post-traumatic headache attributed to mild traumatic brain injury
- Author
-
Ashina, Håkan, Iljazi, Afrim, Al-Khazali, Haidar M., Do, Thien Phu, Eigenbrodt, Anna K., Larsen, Eigil L., Andersen, Amalie M., Hansen, Kevin J., Bräuner, Karoline B., Chaudhry, Basit Ali, Christensen, Casper E., Amin, Faisal Mohammad, and Schytz, Henrik W.
- Published
- 2022
- Full Text
- View/download PDF
7. Induction of cluster headache after opening of adenosine triphosphate-sensitive potassium channels:a randomized clinical trial
- Author
-
Al-Khazali, Haidar M., Deligianni, Christina I., Pellesi, Lanfranco, Al-Karagholi, Mohammad Al Mahdi, Ashina, Håkan, Chaudhry, Basit Ali, Petersen, Anja Sofie, Jensen, Rigmor H., Amin, Faisal Mohammad, Ashina, Messoud, Al-Khazali, Haidar M., Deligianni, Christina I., Pellesi, Lanfranco, Al-Karagholi, Mohammad Al Mahdi, Ashina, Håkan, Chaudhry, Basit Ali, Petersen, Anja Sofie, Jensen, Rigmor H., Amin, Faisal Mohammad, and Ashina, Messoud
- Abstract
Activation of adenosine triphosphate-sensitive potassium (KATP) channels has been implicated in triggering migraine attacks. However, whether the opening of these channels provoke cluster headache attacks remains undetermined. The hallmark of cluster headache is a distinct cyclical pattern of recurrent, severe headache episodes, succeeded by intervals of remission where no symptoms are present. In our study, we enrolled 41 participants: 10 with episodic cluster headaches during a bout, 15 in the attack-free remission period, and 17 diagnosed with chronic cluster headaches. Over 2 distinct experimental days, participants underwent a continuous 20-minute infusion of levcromakalim, a KATP channel opener, or a placebo (isotonic saline), followed by a 90-minute observational period. The primary outcome was comparing the incidence of cluster headache attacks within the postinfusion observation period between the levcromakalim and placebo groups. Six of 10 participants (60%) with episodic cluster headaches in bout experienced attacks after levcromakalim infusion, vs just 1 of 10 (10%) with placebo (P = 0.037). Among those in the remission phase, 1 of 15 participants (7%) reported attacks after levcromakalim, whereas none did postplacebo (P = 0.50). In addition, 5 of 17 participants (29%) with chronic cluster headache had attacks after levcromakalim, in contrast to none after placebo (P = 0.037). These findings demonstrate that KATP channel activation can induce cluster headache attacks in participants with episodic cluster headaches in bout and chronic cluster headache, but not in those in the remission period. Our results underscore the potential utility of KATP channel inhibitors as therapeutic agents for cluster headaches., ABSTRACT: Activation of adenosine triphosphate-sensitive potassium (K ATP ) channels has been implicated in triggering migraine attacks. However, whether the opening of these channels provoke cluster headache attacks remains undetermined. The hallmark of cluster headache is a distinct cyclical pattern of recurrent, severe headache episodes, succeeded by intervals of remission where no symptoms are present. In our study, we enrolled 41 participants: 10 with episodic cluster headaches during a bout, 15 in the attack-free remission period, and 17 diagnosed with chronic cluster headaches. Over 2 distinct experimental days, participants underwent a continuous 20-minute infusion of levcromakalim, a K ATP channel opener, or a placebo (isotonic saline), followed by a 90-minute observational period. The primary outcome was comparing the incidence of cluster headache attacks within the postinfusion observation period between the levcromakalim and placebo groups. Six of 10 participants (60%) with episodic cluster headaches in bout experienced attacks after levcromakalim infusion, vs just 1 of 10 (10%) with placebo ( P = 0.037). Among those in the remission phase, 1 of 15 participants (7%) reported attacks after levcromakalim, whereas none did postplacebo ( P = 0.50). In addition, 5 of 17 participants (29%) with chronic cluster headache had attacks after levcromakalim, in contrast to none after placebo ( P = 0.037). These findings demonstrate that K ATP channel activation can induce cluster headache attacks in participants with episodic cluster headaches in bout and chronic cluster headache, but not in those in the remission period. Our results underscore the potential utility of K ATP channel inhibitors as therapeutic agents for cluster headaches.
- Published
- 2024
8. Effects of PDE-3 inhibition in persistent post-traumatic headache:evidence of cAMP-dependent signaling
- Author
-
Al-Khazali, Haidar M., Christensen, Rune H., Chaudhry, Basit Ali, Melchior, Anna G., Ashina, Messoud, Burstein, Rami, Ashina, Håkan, Al-Khazali, Haidar M., Christensen, Rune H., Chaudhry, Basit Ali, Melchior, Anna G., Ashina, Messoud, Burstein, Rami, and Ashina, Håkan
- Abstract
Background Phosphodiesterase 3 (PDE-3) inhibition have been implicated in the neurobiologic underpinnings of migraine. Considering the clinical similarities between migraine and persistent post-traumatic headache (PPTH), we aimed to ascertain whether PDE-3 inhibition can elicit migraine-like headache in persons with PPTH. Methods We tested cilostazol, which inhibits PDE-3, in a randomized, double-blind, placebo-controlled, two-way crossover study involving persons with PPTH attributed to mild traumatic brain injury. The randomized participants were allocated to receive oral administration of either 200-mg cilostazol or placebo (calcium tablet) on two separate experiment days. The primary end point was the incidence of migraine-like headache during a 12-hour observation window post-ingestion. The secondary endpoint was the area under the curve (AUC) for reported headache intensity scores during the same observation window. Results Twenty-one persons underwent randomization and completed both experiment days. The mean participants’ age was 41.4 years, and most (n = 17) were females. During the 12-hour observation window, 14 (67%) of 21 participants developed migraine-like headache post-cilostazol, in contrast to three (14%) participants after placebo (P =.003). The headache intensity scores were higher post-cilostazol than after placebo (P <.001). Conclusions Our results provide novel evidence showing that PDE-3 inhibition can elicit migraine-like headache in persons with PPTH. Given that PDE-3 inhibition increases intracellular cAMP levels, our findings allude to the potential therapeutic value of targeting cAMP-dependent signaling pathways in the management of PPTH. Further investigations are imperative to substantiate these insights and delineate the importance of cAMP-dependent signaling pathways in the neurobiologic mechanisms underlying PPTH., Background: Phosphodiesterase 3 (PDE-3) inhibition have been implicated in the neurobiologic underpinnings of migraine. Considering the clinical similarities between migraine and persistent post-traumatic headache (PPTH), we aimed to ascertain whether PDE-3 inhibition can elicit migraine-like headache in persons with PPTH. Methods: We tested cilostazol, which inhibits PDE-3, in a randomized, double-blind, placebo-controlled, two-way crossover study involving persons with PPTH attributed to mild traumatic brain injury. The randomized participants were allocated to receive oral administration of either 200-mg cilostazol or placebo (calcium tablet) on two separate experiment days. The primary end point was the incidence of migraine-like headache during a 12-hour observation window post-ingestion. The secondary endpoint was the area under the curve (AUC) for reported headache intensity scores during the same observation window. Results: Twenty-one persons underwent randomization and completed both experiment days. The mean participants’ age was 41.4 years, and most (n = 17) were females. During the 12-hour observation window, 14 (67%) of 21 participants developed migraine-like headache post-cilostazol, in contrast to three (14%) participants after placebo (P =.003). The headache intensity scores were higher post-cilostazol than after placebo (P <.001). Conclusions: Our results provide novel evidence showing that PDE-3 inhibition can elicit migraine-like headache in persons with PPTH. Given that PDE-3 inhibition increases intracellular cAMP levels, our findings allude to the potential therapeutic value of targeting cAMP-dependent signaling pathways in the management of PPTH. Further investigations are imperative to substantiate these insights and delineate the importance of cAMP-dependent signaling pathways in the neurobiologic mechanisms underlying PPTH. ClinicalTrials.gov Identifier: NCT05595993.
- Published
- 2024
9. Hypersensitivity to PACAP-38 in post-traumatic headache:a randomized clinical trial
- Author
-
Al-Khazali, Haidar M., Christensen, Rune H., Dodick, David W., Chaudhry, Basit Ali, Amin, Faisal Mohammad, Burstein, Rami, Ashina, Håkan, Al-Khazali, Haidar M., Christensen, Rune H., Dodick, David W., Chaudhry, Basit Ali, Amin, Faisal Mohammad, Burstein, Rami, and Ashina, Håkan
- Abstract
Pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), known for its role in migraine pathogenesis, has been identified as a novel drug target. Given the clinical parallels between post-traumatic headache (PTH) and migraine, we explored the possible role of PACAP-38 in the pathogenesis of PTH. To this end, we conducted a randomized, double-blind, placebo-controlled, two-way crossover trial involving adult participants diagnosed with persistent PTH resulting from mild traumatic brain injury. Participants were randomly assigned to receive a 20-min continuous intravenous infusion of either PACAP-38 (10 pmol/kg/min) or placebo (isotonic saline) on two separate experimental days, with a 1-week washout period in between. The primary outcome was the difference in incidence of migraine-like headache between PACAP-38 and placebo during a 12-h observational period post-infusion. The secondary outcome was the difference in the area under the curve (AUC) for baseline-corrected median headache intensity scores during the same 12-h observational period. Of 49 individuals assessed for eligibility, 21 were enrolled and completed the trial. The participants had a mean age of 35.2 years, and 16 (76%) were female. Most [19 of 21 (90%)] had a migraine-like phenotype. During the 12-h observational period, 20 of 21 (95%) participants developed migraine-like headache after intravenous infusion of PACAP-38, compared with two (10%) participants after placebo (P < 0.001). Furthermore, the baseline-corrected AUC values for median headache intensity scores during the 12-h observational period was higher after PACAP-38 than placebo (P < 0.001). These compelling results demonstrate that PACAP-38 is potent inducer of migraine-like headache in people with persistent PTH. Thus, targeting PACAP-38 signalling might be a promising avenue for the treatment of PTH., Pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), known for its role in migraine pathogenesis, has been identified as a novel drug target. Given the clinical parallels between post-traumatic headache (PTH) and migraine, we explored the possible role of PACAP-38 in the pathogenesis of PTH. To this end, we conducted a randomized, double-blind, placebo-controlled, 2-way crossover trial involving adult participants diagnosed with persistent PTH resulting from mild traumatic brain injury. Participants were randomly assigned to receive a 20-minute continuous intravenous infusion of either PACAP-38 (10 pmol/kg/min) or placebo (isotonic saline) on two separate experimental days, with a 1-week wash-out period in between. The primary outcome was the difference in incidence of migraine-like headache between PACAP-38 and placebo during a 12-hour observational period post-infusion. The secondary outcome was the difference in the area under the curve (AUC) for baseline-corrected median headache intensity scores during the same 12-hour observational period. Of 49 individuals assessed for eligibility, 21 were enrolled and completed the trial. The participants had a mean age of 35.2 years, and 16 (76%) were women. Most of them (19 [90%] of 21) had a migraine-like phenotype. During the 12-hour observational period, 20 (95%) of 21 participants developed migraine-like headache after intravenous infusion of PACAP-38, compared with 2 (10%) participants after placebo (P < 0.001). Furthermore, the baseline-corrected AUC values for median headache intensity scores during the 12-hour observational period was higher after PACAP-38 than placebo (P < 0.001). These compelling results demonstrate that PACAP-38 is potent inducer of migraine-like headache in people with persistent PTH. Thus, targeting PACAP-38 signalling might be a promising avenue for the treatment of PTH.
- Published
- 2024
10. Activation of ATP-sensitive potassium channels triggers migraine attacks independent of calcitonin gene-related peptide receptors:a randomized placebo-controlled trial
- Author
-
Raffaelli, Bianca, Do, Thien Phu, Chaudhry, Basit Ali, Amin, Faisal Mohammad, Ashina, Håkan, Snellman, Josefin, Maio-Twofoot, Tina, Ashina, Messoud, Raffaelli, Bianca, Do, Thien Phu, Chaudhry, Basit Ali, Amin, Faisal Mohammad, Ashina, Håkan, Snellman, Josefin, Maio-Twofoot, Tina, and Ashina, Messoud
- Abstract
Background The present study aimed to investigate whether levcromakalim, a KATP channel opener, induces migraine attacks in people with migraine pre-treated with erenumab, a monoclonal CGRP receptor antibody. Methods In this double-blind, placebo-controlled, two-way cross-over study, adults with migraine without aura received a subcutaneous injection of 140 mg of erenumab on day 1. Subsequently, they were randomized to receive a 20-minute infusion of 0.05 mg/ml levcromakalim or placebo on two experimental days separated by at least one week (between days 8 and 21). The primary endpoint was the difference in the incidence of migraine attacks between levcromakalim and placebo during the 12-hour post-infusion period. Results In total, 16 participants completed the study. During the 12-hour observation period, 14 (88%) of 16 participants experienced migraine attacks after levcromakalim, compared to two (12%) after placebo (p < 0.001). The area under the curve for median headache intensity was greater after levcromakalim than placebo (p < 0.001). Levcromakalim elicited dilation of the superficial temporal artery during the first hour after infusion, a response absent following placebo (p < 0.001). Conclusions The induction of migraine attacks via opening of KATP channels appears independent of CGRP receptor activation., BACKGROUND: The present study aimed to investigate whether levcromakalim, a KATP channel opener, induces migraine attacks in people with migraine pre-treated with erenumab, a monoclonal CGRP receptor antibody. METHODS: In this double-blind, placebo-controlled, two-way cross-over study, adults with migraine without aura received a subcutaneous injection of 140 mg of erenumab on day 1. Subsequently, they were randomized to receive a 20-minute infusion of 0.05 mg/ml levcromakalim or placebo on two experimental days separated by at least one week (between days 8 and 21). The primary endpoint was the difference in the incidence of migraine attacks between levcromakalim and placebo during the 12-hour post-infusion period. RESULTS: In total, 16 participants completed the study. During the 12-hour observation period, 14 (88%) of 16 participants experienced migraine attacks after levcromakalim, compared to two (12%) after placebo (p < 0.001). The area under the curve for median headache intensity was greater after levcromakalim than placebo (p < 0.001). Levcromakalim elicited dilation of the superficial temporal artery during the first hour after infusion, a response absent following placebo (p < 0.001). CONCLUSIONS: The induction of migraine attacks via opening of KATP channels appears independent of CGRP receptor activation.Trial Registration: ClinicalTrials.gov, Identifier NCT05889442.
- Published
- 2024
11. Hypersensitivity to BKCa channel opening in persistent post-traumatic headache.
- Author
-
Al-Khazali, Haidar M., Christensen, Rune H., Dodick, David W., Chaudhry, Basit Ali, Melchior, Anna G., Burstein, Rami, and Ashina, Håkan
- Subjects
PLACEBOS ,RECEIVER operating characteristic curves ,RESEARCH funding ,HEADACHE ,BLIND experiment ,TREATMENT effectiveness ,RANDOMIZED controlled trials ,DESCRIPTIVE statistics ,INDOLE compounds ,CROSSOVER trials ,BRAIN injuries ,ION channels ,DRUG discovery ,DISEASE risk factors - Abstract
Background: Large conductance calcium-activated potassium (BK
Ca ) channels have been implicated in the neurobiological underpinnings of migraine. Considering the clinical similarities between migraine and persistent post-traumatic headache (PPTH), we aimed to examine whether MaxiPost (a BKCa channel opener) could induce migraine-like headache in persons with PPTH. Methods: This is a randomized double-blind, placebo-controlled, two-way crossover study from September 2023 to December 2023. Eligible participants were adults with PPTH after mild traumatic brain injury who reported having no personal history of migraine. The randomized participants received a single dose of either MaxiPost (0.05 mg/min) or placebo (isotonic saline) that was infused intravenously over 20 minutes. The two experiment sessions were scheduled at least one week apart to avoid potential carryover effects. The primary endpoint was the induction of migraine-like headache after MaxiPost as compared to placebo within 12 hours of drug administration. The secondary endpoint was the area under the curve (AUC) values for headache intensity scores between MaxiPost and placebo over the same 12-hour observation period. Results: Twenty-one adult participants (comprising 14 females and 7 males) with PPTH were enrolled and completed both experiment sessions. The proportion of participants who developed migraine-like headache was 11 (52%) of 21 participants after MaxiPost infusion, in contrast to four (19%) participants following placebo (P =.02). Furthermore, the median headache intensity scores, represented by AUC values, were higher following MaxiPost than after placebo (P <.001). Conclusions: Our results indicate that BKCa channel opening can elicit migraine-like headache in persons with PPTH. Thus, pharmacologic blockade of BKCa channels might present a novel avenue for drug discovery. Additional investigations are nonetheless needed to confirm these insights and explore the therapeutic prospects of BKCa channel blockers in managing PPTH. ClinicalTrials.gov Identifier: NCT05378074. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
12. Induction of cluster headache after opening of adenosine triphosphate-sensitive potassium channels: a randomized clinical trial.
- Author
-
Al-Khazali, Haidar M., Deligianni, Christina I., Pellesi, Lanfranco, Al-Karagholi, Mohammad Al-Mahdi, Ashina, Håkan, Chaudhry, Basit Ali, Petersen, Anja Sofie, Jensen, Rigmor H., Amin, Faisal Mohammad, and Ashina, Messoud
- Published
- 2024
- Full Text
- View/download PDF
13. Activation of ATP-sensitive potassium channels triggers migraine attacks independent of calcitonin gene-related peptide receptors: a randomized placebo-controlled trial
- Author
-
Raffaelli, Bianca, primary, Do, Thien Phu, additional, Chaudhry, Basit Ali, additional, Amin, Faisal Mohammad, additional, Ashina, Håkan, additional, Snellman, Josefin, additional, Maio-Twofoot, Tina, additional, and Ashina, Messoud, additional
- Published
- 2024
- Full Text
- View/download PDF
14. Induction of cluster headache after opening of adenosine triphosphate-sensitive potassium channels: a randomized clinical trial
- Author
-
Al-Khazali, Haidar M., primary, Deligianni, Christina I., additional, Pellesi, Lanfranco, additional, Al-Karagholi, Mohammad Al-Mahdi, additional, Ashina, Håkan, additional, Chaudhry, Basit Ali, additional, Petersen, Anja Sofie, additional, Jensen, Rigmor H., additional, Amin, Faisal Mohammad, additional, and Ashina, Messoud, additional
- Published
- 2023
- Full Text
- View/download PDF
15. The Impact of Biosimilar Use on Total Cost of Care and Provider Financial Performance in the Medicare Oncology Care Model: A Population-Based Simulation Study
- Author
-
Yang, Jingyan, primary, Chaudhry, Basit I., additional, Yue, Andrew T., additional, Roth, Joshua A., additional, Kelton, John M., additional, Shelbaya, Ahmed, additional, Tran, Lisa, additional, and Li, Meng, additional
- Published
- 2023
- Full Text
- View/download PDF
16. Hypersensitivity to PACAP-38 in post-traumatic headache: a randomized clinical trial.
- Author
-
Al-Khazali, Haidar M, Christensen, Rune H, Dodick, David W, Chaudhry, Basit Ali, Amin, Faisal Mohammad, Burstein, Rami, and Ashina, Håkan
- Subjects
PITUITARY adenylate cyclase activating polypeptide ,CLINICAL trials ,HEADACHE ,BRAIN injuries ,INTRAVENOUS therapy ,MIGRAINE aura - Abstract
Pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), known for its role in migraine pathogenesis, has been identified as a novel drug target. Given the clinical parallels between post-traumatic headache (PTH) and migraine, we explored the possible role of PACAP-38 in the pathogenesis of PTH. To this end, we conducted a randomized, double-blind, placebo-controlled, two-way crossover trial involving adult participants diagnosed with persistent PTH resulting from mild traumatic brain injury. Participants were randomly assigned to receive a 20-min continuous intravenous infusion of either PACAP-38 (10 pmol/kg/min) or placebo (isotonic saline) on two separate experimental days, with a 1-week washout period in between. The primary outcome was the difference in incidence of migraine-like headache between PACAP-38 and placebo during a 12-h observational period post-infusion. The secondary outcome was the difference in the area under the curve (AUC) for baseline-corrected median headache intensity scores during the same 12-h observational period. Of 49 individuals assessed for eligibility, 21 were enrolled and completed the trial. The participants had a mean age of 35.2 years, and 16 (76%) were female. Most [19 of 21 (90%)] had a migraine-like phenotype. During the 12-h observational period, 20 of 21 (95%) participants developed migraine-like headache after intravenous infusion of PACAP-38, compared with two (10%) participants after placebo (P < 0.001). Furthermore, the baseline-corrected AUC values for median headache intensity scores during the 12-h observational period was higher after PACAP-38 than placebo (P < 0.001). These compelling results demonstrate that PACAP-38 is potent inducer of migraine-like headache in people with persistent PTH. Thus, targeting PACAP-38 signalling might be a promising avenue for the treatment of PTH. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Real-world efficacy and tolerability of fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, observational study
- Author
-
Cullum, Christopher Kjaer, primary, Chaudhry, Basit Ali, additional, Do, Thien Phu, additional, and Amin, Faisal Mohammad, additional
- Published
- 2023
- Full Text
- View/download PDF
18. Improved Osteoarthritis during Erenumab Treatment for Migraine: A Case Report
- Author
-
Jantzen, Frederik Thal, primary, Christensen, Rune Häckert, additional, Chaudhry, Basit Ali, additional, and Amin, Faisal Mohammad, additional
- Published
- 2023
- Full Text
- View/download PDF
19. Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study
- Author
-
Ashina, Håkan, Iljazi, Afrim, Al-Khazali, Haidar Muhsen, Eigenbrodt, Anna Kristina, Larsen, Eigil Lindekilde, Andersen, Amalie Middelboe, Hansen, Kevin John, Bräuner, Karoline Bendix, Mørch-Jessen, Thomas, Chaudhry, Basit, Antic, Sonja, Christensen, Casper Emil, Ashina, Messoud, Amin, Faisal Mohammad, and Schytz, Henrik Winther
- Published
- 2020
- Full Text
- View/download PDF
20. Plasma levels of VIP are not elevated during PACAP- and VIP-induced cluster headache attacks: an exploratory study
- Author
-
Deligianni, Christina, primary, Pellesi, Lanfranco, additional, Chaudhry, Basit Ali, additional, Haulund Vollesen, Anne Luise, additional, Snoer, Agneta Henriette, additional, Hannibal, Jens, additional, Jensen, Rigmor Højland, additional, and Ashina, Messoud, additional
- Published
- 2023
- Full Text
- View/download PDF
21. Improved Osteoarthritis during Erenumab Treatment for Migraine:A Case Report
- Author
-
Jantzen, Frederik Thal, Christensen, Rune Häckert, Chaudhry, Basit Ali, Amin, Faisal Mohammad, Jantzen, Frederik Thal, Christensen, Rune Häckert, Chaudhry, Basit Ali, and Amin, Faisal Mohammad
- Abstract
Antibodies blocking the calcitonin gene-related peptide have revolutionized episodic and chronic migraine treatment. However, their applicability to non-cephalic pain conditions, such as osteoarthritis, is yet unknown. Osteoarthritis remains a clinical challenge, associated with high disability and limited treatment options. Like migraine, neuropeptides including calcitonin gene-related peptides are involved in its pathophysiology. We present the first case of a patient: a 73-year-old female with osteoarthritis who received monthly treatment for her chronic migraine with 140 mg subcutaneous erenumab, a monoclonal antibody against the receptor of calcitonin gene-related peptide. Though the migraine was unresponsive, the patient's arthritic symptoms improved drastically during treatment period with erenumab; daily pain decreased from VAS 7 to 2, and walking distance doubled from 1,000 m to 2,000 m. The arthritic symptoms relapsed after discontinuation of erenumab. Erenumab could potentially have beneficial effects on symptoms of osteoarthritis. Future studies investigating these effects are warranted.
- Published
- 2023
22. Menstrual migraine is caused by estrogen withdrawal:revisiting the evidence
- Author
-
Raffaelli, Bianca, Do, Thien Phu, Chaudhry, Basit Ali, Ashina, Messoud, Amin, Faisal Mohammad, Ashina, Håkan, Raffaelli, Bianca, Do, Thien Phu, Chaudhry, Basit Ali, Ashina, Messoud, Amin, Faisal Mohammad, and Ashina, Håkan
- Abstract
Objective To explore and critically appraise the evidence supporting the role of estrogen withdrawal in menstrual migraine. Main body Menstrual migraine, impacting about 6% of reproductive-age women, manifests as migraine attacks closely related to the menstrual cycle. The estrogen withdrawal hypothesis posits that the premenstrual drop in estrogen levels serves as a trigger of migraine attacks. Despite its wide acceptance, the current body of evidence supporting this hypothesis remains limited, warranting further validation. Estrogen is believed to exert a modulatory effect on pain, particularly within the trigeminovascular system – the anatomic and physiologic substrate of migraine pathogenesis. Nevertheless, existing studies are limited by methodologic inconsistencies, small sample sizes, and variable case definitions, precluding definitive conclusions. To improve our understanding of menstrual migraine, future research should concentrate on untangling the intricate interplay between estrogen, the trigeminovascular system, and migraine itself. This necessitates the use of robust methods, larger sample sizes, and standardized case definitions to surmount the limitations encountered in previous investigations. Conclusion Further research is thus needed to ascertain the involvement of estrogen withdrawal in menstrual migraine and advance the development of effective management strategies to address unmet treatment needs., Objective: To explore and critically appraise the evidence supporting the role of estrogen withdrawal in menstrual migraine. Main body: Menstrual migraine, impacting about 6% of reproductive-age women, manifests as migraine attacks closely related to the menstrual cycle. The estrogen withdrawal hypothesis posits that the premenstrual drop in estrogen levels serves as a trigger of migraine attacks. Despite its wide acceptance, the current body of evidence supporting this hypothesis remains limited, warranting further validation. Estrogen is believed to exert a modulatory effect on pain, particularly within the trigeminovascular system – the anatomic and physiologic substrate of migraine pathogenesis. Nevertheless, existing studies are limited by methodologic inconsistencies, small sample sizes, and variable case definitions, precluding definitive conclusions. To improve our understanding of menstrual migraine, future research should concentrate on untangling the intricate interplay between estrogen, the trigeminovascular system, and migraine itself. This necessitates the use of robust methods, larger sample sizes, and standardized case definitions to surmount the limitations encountered in previous investigations. Conclusion: Further research is thus needed to ascertain the involvement of estrogen withdrawal in menstrual migraine and advance the development of effective management strategies to address unmet treatment needs.
- Published
- 2023
23. Plasma levels of VIP are not elevated during PACAP- and VIP-induced cluster headache attacks:an exploratory study
- Author
-
Deligianni, Christina, Pellesi, Lanfranco, Chaudhry, Basit Ali, Haulund Vollesen, Anne Luise, Snoer, Agneta Henriette, Hannibal, Jens, Jensen, Rigmor Højland, Ashina, Messoud, Deligianni, Christina, Pellesi, Lanfranco, Chaudhry, Basit Ali, Haulund Vollesen, Anne Luise, Snoer, Agneta Henriette, Hannibal, Jens, Jensen, Rigmor Højland, and Ashina, Messoud
- Abstract
Background: Pituitary adenylate cyclase-activating peptide (PACAP) and vasoactive intestinal peptide (VIP) provoked cluster headache attacks in individuals with episodic cluster headache during their active phase and individuals with chronic cluster headache. In this study, we investigated whether infusions of PACAP and VIP caused alterations in plasma levels of VIP and their potential contribution to induced cluster headache attacks. Methods: Participants received either PACAP or VIP infusion for 20 min on 2 separate days with an interval of at least 7 days in between. Blood collection was performed at T0, T20, T30, and T90. Plasma levels of VIP were measured using a validated radioimmunoassay method. Results: Blood samples were collected from participants with episodic cluster headache in the active phase (eCHA, n = 14), remission (eCHR, n = 15), and from participants with chronic cluster headache (cCH, n = 15). Baseline levels of VIP did not differ among the three groups (p = 0.1161). During PACAP infusion, mixed-effects analysis revealed a significant increase in plasma levels of VIP in eCHA (p = 0.0300) and eCHR (p = 0.0058) but not in cCH (p = 0.2930). We found no difference in the increase of plasma VIP levels between patients who developed PACAP38- or VIP-induced attacks. Conclusion: Cluster headache attacks induced by PACAP38 or VIP infusion are not associated with changes in plasma levels of VIP. Further studies are needed to investigate the role of VIP and the parasympathetic system in cluster headache. Clinical trial registration: The parent study is registered at ClinicalTrials.gov (NCT03814226).
- Published
- 2023
24. Real-world efficacy and tolerability of fremanezumab in adults with chronic migraine:a 3-month, single-center, prospective, observational study
- Author
-
Cullum, Christopher Kjaer, Chaudhry, Basit Ali, Do, Thien Phu, Amin, Faisal Mohammad, Cullum, Christopher Kjaer, Chaudhry, Basit Ali, Do, Thien Phu, and Amin, Faisal Mohammad
- Abstract
Background: Following the promising pre-marketing placebo-controlled randomized clinical trials of fremanezumab, post-marketing studies are necessary to verify efficacy and tolerability in various real-world settings. The present study assessed real-world efficacy and safety of fremanezumab. Methods: A 3-month, single-center, prospective, observation study of adults with chronic migraine who were treated with monthly subcutaneous injections of 225 mg fremanezumab in Denmark. The primary outcome was defined as proportion of patients who achieved ≥30% reduction in monthly migraine days (MMDs) from baseline to weeks 9–12. Among secondary outcomes were ≥50 and ≥75% responder rates and the proportion of patients reporting adverse events. Results: A total of 91 patients with chronic migraine were enrolled and received at least one dose of fremanezumab of whom 89 patients (98%) completed the 3-months treatment period. At baseline, the mean (SD) number of monthly headache days was 24.3 ± 5.8 and mean number of MMDs was 18.5 ± 7.4. The number of patients who achieved ≥30% reduction in MMDs from baseline to weeks 9–12 was 58 (65%), while 45 (51%) and 21 (24%) had ≥50 and 75% reduction in MMD, respectively. Twenty-one patients (23%) reported adverse event, in which the most common were constipation (4.4%), fatigue (4.4%) and dizziness (3.3%). No serious adverse events were reported. Conclusion: In adult chronic migraine patients with previous failure of conventional oral migraine preventives, fremanezumab was found to be effective and well-tolerated.
- Published
- 2023
25. Hypersensitivity to opening of ATP-sensitive potassium channels in post-traumatic headache
- Author
-
Al-Khazali, Haidar M., Christensen, Rune H., Dodick, David W., Chaudhry, Basit Ali, Burstein, Rami, Ashina, Håkan, Al-Khazali, Haidar M., Christensen, Rune H., Dodick, David W., Chaudhry, Basit Ali, Burstein, Rami, and Ashina, Håkan
- Abstract
Objective To investigate whether levcromakalim (a KATP channel opener) induces migraine-like headache in people with persistent post-traumatic headache who had no known history of migraine. Methods In a randomized, double-blind, placebo-controlled, 2-way crossover trial, participants were randomly assigned to receive a 20-minute continuous intravenous infusion of levcromakalim (50 µg/mL) or placebo (isotonic saline) on two separate experimental days with a 1-week wash-out period in between. The primary endpoint was the difference in incidence of migraine-like headache between levcromakalim and placebo during a 12-hour observational period after infusion start. The secondary endpoint was the difference in area under the curve for baseline-corrected median headache intensity scores between levcromakalim and placebo during the 12-hour observational period. Results A total of 21 participants with persistent post-traumatic headache were randomized and completed the trial. During the 12-hour observational period, 12 (57%) of 21 participants reported experiencing migraine-like headache following the levcromakalim infusion, compared with three after placebo (P = 0.013). Moreover, the baseline-corrected median headache intensity scores were higher following the levcromakalim infusion than after placebo (P = 0.003). Conclusion Our findings suggest that KATP channels play an important role in the pathogenesis of migraine-like headache in people with persistent post-traumatic headache. This implies that KATP channel blockers might represent a promising avenue for drug development. Further research is warranted to explore the potential therapeutic benefits of KATP channel blockers in managing post-traumatic headache., OBJECTIVE: To investigate whether levcromakalim (a KATP channel opener) induces migraine-like headache in people with persistent post-traumatic headache who had no known history of migraine. METHODS: In a randomized, double-blind, placebo-controlled, 2-way crossover trial, participants were randomly assigned to receive a 20-minute continuous intravenous infusion of levcromakalim (50 µg/mL) or placebo (isotonic saline) on two separate experimental days with a 1-week wash-out period in between. The primary endpoint was the difference in incidence of migraine-like headache between levcromakalim and placebo during a 12-hour observational period after infusion start. The secondary endpoint was the difference in area under the curve for baseline-corrected median headache intensity scores between levcromakalim and placebo during the 12-hour observational period. RESULTS: A total of 21 participants with persistent post-traumatic headache were randomized and completed the trial. During the 12-hour observational period, 12 (57%) of 21 participants reported experiencing migraine-like headache following the levcromakalim infusion, compared with three after placebo (P = 0.013). Moreover, the baseline-corrected median headache intensity scores were higher following the levcromakalim infusion than after placebo (P = 0.003). CONCLUSION: Our findings suggest that KATP channels play an important role in the pathogenesis of migraine-like headache in people with persistent post-traumatic headache. This implies that KATP channel blockers might represent a promising avenue for drug development. Further research is warranted to explore the potential therapeutic benefits of KATP channel blockers in managing post-traumatic headache.Trial Registration: ClinicalTrials.gov Identifier: NCT05243953.
- Published
- 2023
26. Cluster headache – The worst possible pain on YouTube
- Author
-
Chaudhry, Basit Ali, primary, Do, Thien Phu, additional, Ashina, Håkan, additional, Ashina, Messoud, additional, and Amin, Faisal Mohammad, additional
- Published
- 2022
- Full Text
- View/download PDF
27. The Registry for Migraine (REFORM) study: methodology, demographics, and baseline clinical characteristics.
- Author
-
Karlsson, William Kristian, Ashina, Håkan, Cullum, Christopher Kjær, Christensen, Rune Häckert, Al-Khazali, Haidar Muhsen, Amin, Faisal Mohammad, Ashina, Messoud, Iljazi, Afrim, Thomsen, Andreas Vinther, Chaudhry, Basit Ali, Tesfay, Betel, Thuraiaiyah, Janu, Kokoti, Lili, Rasmussen, Nadja Bredo, Domínguez-Moreno, Rogelio, Do, Thien Phu, and Zhuang, Zixuan Alice
- Subjects
MIGRAINE prevention ,THERAPEUTIC use of monoclonal antibodies ,BIOMARKERS ,DRUG efficacy ,INTRAVENOUS therapy ,CLINICAL trials ,MIGRAINE ,NEUROPEPTIDES ,RESEARCH methodology ,PHLEBOTOMY ,MAGNETIC resonance imaging ,INTERVIEWING ,HEALTH outcome assessment ,MONOCLONAL antibodies ,CASE-control method ,DIARY (Literary form) ,SYMPTOMS ,DESCRIPTIVE statistics ,RESEARCH funding ,HEADACHE ,SUBCUTANEOUS infusions ,LONGITUDINAL method - Abstract
Background: Erenumab has demonstrated effectiveness for prevention of migraine attacks, but the treatment is costly, and a considerable proportion of patients do not respond to it. The Registry for Migraine study (REFORM) was initiated to discover biomarkers that can predict response to erenumab in patients with migraine. The specific objective was to investigate differences in erenumab efficacy based on clinical information, blood-based biomarkers, structural and functional magnetic resonance imaging (MRI), and response to intravenous infusion of calcitonin gene-related peptide (CGRP). In this first report of the REFORM study, we provide a comprehensive description of the study methodology, and present the baseline characteristics of the study population. Methods: The REFORM study was a single-center, prospective, longitudinal cohort study in adults with migraine who were scheduled to receive preventive treatment with erenumab as part of a separate, open-label, single-arm phase IV trial. The study included four periods: a 2-week screening period (Weeks -6 to -5), 4-week baseline period (Week -4 to Day 1), 24-week treatment period (Day 1 to Week 24), and a 24-week follow-up period without treatment (Week 25 to Week 48). Demographic and clinical characteristics were recorded using a semi-structured interview, whilst outcome data were obtained using a headache diary, patient-reported outcomes, blood sampling, brain MRI, and responsiveness to intravenous infusion of CGRP. Results: The study enrolled 751 participants, with a mean age ± SD of 43.8 ± 12.2 years, of which 88.8% (n = 667) were female. At enrollment, 64.7% (n = 486) were diagnosed with chronic migraine, and 30.2% (n = 227) had history of aura. The mean monthly migraine days (MMDs) was 14.5 ± 7.0. Concomitant preventive medications were used by 48.5% (n = 364) of the participants, and 39.9% (n = 300) had failed ≥ 4 preventive medications. Conclusion: The REFORM study enrolled a population with a high migraine burden and frequent use of concomitant medications. The baseline characteristics were representative of patients with migraine in specialized headache clinics. Future publications will report the results of the investigations presented in this article. Trial registration: The study and sub-studies were registered on ClinicalTrials.gov (NCT04592952; NCT04603976; and NCT04674020). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. Projected impact of oncology biosimilar substitution from the perspective of provider risk in value-based oncology payment models.
- Author
-
Yang, Jingyan, primary, Chaudhry, Basit Iqbal, additional, Yue, Andrew, additional, Kelton, John M., additional, Shelbaya, Ahmed, additional, Tran, Lisa, additional, and Li, Meng, additional
- Published
- 2022
- Full Text
- View/download PDF
29. Corrigendum to: PACAP38- and VIP-induced cluster headache attacks are not associated with changes of plasma CGRP or markers of mast cell activation
- Author
-
Pellesi, Lanfranco, primary, Chaudhry, Basit Ali, additional, Vollesen, Anne Luise Haulund, additional, Snoer, Agneta Henriette, additional, Baumann, Katrine, additional, Skov, Per Stahl, additional, Jensen, Rigmor Højland, additional, and Ashina, Messoud, additional
- Published
- 2022
- Full Text
- View/download PDF
30. Plasma Levels of CGRP During a 2-h Infusion of VIP in Healthy Volunteers and Patients With Migraine:An Exploratory Study
- Author
-
Pellesi, Lanfranco, Al-Karagholi, Mohammad Al Mahdi, De Icco, Roberto, Chaudhry, Basit Ali, Lopez, Cristina Lopez, Snellman, Josefin, Hannibal, Jens, Amin, Faisal Mohammad, Ashina, Messoud, Pellesi, Lanfranco, Al-Karagholi, Mohammad Al Mahdi, De Icco, Roberto, Chaudhry, Basit Ali, Lopez, Cristina Lopez, Snellman, Josefin, Hannibal, Jens, Amin, Faisal Mohammad, and Ashina, Messoud
- Abstract
Introduction: The activation of perivascular fibers and the consequent release of vasoactive peptides, including the vasoactive intestinal polypeptide (VIP), play a role in migraine pathogenesis. A 2-h infusion of VIP provoked migraine, but the mechanisms remain unknown. We investigated whether 2-h infusion of VIP caused alterations in plasma levels of the calcitonin gene-related peptide (CGRP) and whether any changes might be related to the induced migraine attacks. Materials and Methods: We enrolled individuals with episodic migraine without aura and healthy participants to randomly receive a 2-h infusion of either VIP (8 pmol/kg/min) or placebo (sterile saline) in two randomized, placebo-controlled crossover trials. We collected clinical data and measured plasma levels of VIP and CGRP at fixed time points: at baseline (T0) and every 30 min until 180 min (T180) after the start of the infusion. Results: Blood samples were collected from patients with migraine (n = 19) and healthy individuals (n = 12). During VIP infusion, mixed effects analysis revealed a significant increase in plasma CGRP (p = 0.027) at T30 (vs. T180, adjusted p-value = 0.039) and T60 (vs. T180, adjusted p-value = 0.027) in patients with migraine. We found no increase in plasma CGRP during VIP-induced migraine attacks (p = 0.219). In healthy individuals, there was no increase in plasma CGRP during VIP (p = 0.205) or placebo (p = 0.428) days. Discussion: Plasma CGRP was elevated in patients with migraine during a prolonged infusion of VIP, but these alterations were not associated with VIP-induced migraine attacks. Given the exploratory design of our study, further investigations are needed to clarify the role of CGRP in VIP-induced migraine. Clinical Trial Registration: ClinicalTrials.gov, identifier: NCT03989817 and NCT04260035.
- Published
- 2022
31. Cluster headache – The worst possible pain on YouTube
- Author
-
Chaudhry, Basit Ali, Do, Thien Phu, Ashina, Håkan, Ashina, Messoud, Amin, Faisal Mohammad, Chaudhry, Basit Ali, Do, Thien Phu, Ashina, Håkan, Ashina, Messoud, and Amin, Faisal Mohammad
- Abstract
In clinical practice, patients with cluster headache often ask questions or mention information that they have seen or heard on the Internet. Because YouTube (www.youtube.com) is the second most visited Web site worldwide and offers a plethora of video content, we found it timely to ascertain the quality of information on cluster headache that is freely available on YouTube. We conducted an inquiry on YouTube on January 24, 2022, with the search term “cluster headache.” Eligible YouTube videos included those with ≥10,000 views and content related to cluster headache. We assessed the quality and reliability of the videos with the Global Quality Scale and DISCERN, respectively. The search strategy identified 644 videos of which 134 were eligible for inclusion. The sources of the included videos were categorized as “healthcare professional/institution” (n = 45), “personal experience” (n = 52), and “other” (n = 37). According to the Global Quality Scale, 70 (52%) were low quality, 34 (25%) were of moderate quality, and 30 (22%) were of high quality. According to DISCERN, 104 (78%) were of low reliability, 28 (21%) were of moderate reliability, and 2 (1%) were of high reliability. The quality and reliability of cluster headache-related information on YouTube has room for improvement, even the content provided by healthcare providers. These findings should incentivize stakeholders, for example, government services, professional societies, healthcare providers, to provide accessible and better information on cluster headache.
- Published
- 2022
32. PACAP38- and VIP-induced cluster headache attacks are not associated with changes of plasma CGRP or markers of mast cell activation
- Author
-
Pellesi, Lanfranco, Chaudhry, Basit Ali, Vollesen, Anne Luise Haulund, Snoer, Agneta Henriette, Baumann, Katrine, Skov, Per Stahl, Jensen, Rigmor Højland, Ashina, Messoud, Pellesi, Lanfranco, Chaudhry, Basit Ali, Vollesen, Anne Luise Haulund, Snoer, Agneta Henriette, Baumann, Katrine, Skov, Per Stahl, Jensen, Rigmor Højland, and Ashina, Messoud
- Abstract
Background Pituitary adenylate cyclase-activating polypeptide-38 (PACAP38) and vasoactive intestinal polypeptide can provoke cluster headache attacks in up to half of cluster headache patients in their active phase. At present, it is unknown whether provoked attacks are mediated via calcitonin gene-related peptide or mast cell activation. Methods All enrolled patients with cluster headache were randomly allocated to receive a continuous infusion of either PACAP38 (10 pmol/kg/min) or vasoactive intestinal polypeptide (8 pmol/kg/min) over 20 min. We collected clinical data and measured plasma levels of calcitonin gene-related peptide and markers of mast cell activation (tryptase and histamine) at fixed time points: at baseline (T0), at the end of the infusion (T20), 10 min after the infusion (T30), and 70 min after the infusion (T90). Results Blood was collected from episodic cluster headache patients in active phase (n = 14), episodic cluster headache patients in remission (n = 15), and chronic cluster headache patients (n = 15). At baseline, plasma levels of calcitonin gene-related peptide, tryptase, and histamine were not different among the three study groups. Plasma levels of calcitonin gene-related peptide (p = 0.7074), tryptase (p = 0.6673), or histamine (p = 0.4792) remained unchanged during provoked attacks compared to attack-free patients. Conclusion Cluster headache attacks provoked by either PACAP38 or vasoactive intestinal polypeptide were not accompanied by alterations of plasma calcitonin gene-related peptide, tryptase or histamine. The provoked attacks may not be mediated by calcitonin gene-related peptide or mast cell activation.
- Published
- 2022
33. Plasma Levels of CGRP During a 2-h Infusion of VIP in Healthy Volunteers and Patients With Migraine: An Exploratory Study
- Author
-
Pellesi, Lanfranco, primary, Al-Karagholi, Mohammad Al-Mahdi, additional, De Icco, Roberto, additional, Chaudhry, Basit Ali, additional, Lopez, Cristina Lopez, additional, Snellman, Josefin, additional, Hannibal, Jens, additional, Amin, Faisal Mohammad, additional, and Ashina, Messoud, additional
- Published
- 2022
- Full Text
- View/download PDF
34. PACAP38- and VIP-induced cluster headache attacks are not associated with changes of plasma CGRP or markers of mast cell activation
- Author
-
Pellesi, Lanfranco, primary, Chaudhry, Basit Ali, additional, Vollesen, Anne Luise Haulund, additional, Snoer, Agneta Henriette, additional, Baumann, Katrine, additional, Skov, Per Stahl, additional, Jensen, Rigmor Højland, additional, and Ashina, Messoud, additional
- Published
- 2021
- Full Text
- View/download PDF
35. Moving Forward in GME Reform: A 4 + 1 Model of Resident Ambulatory Training
- Author
-
Chaudhry, Saima I., Balwan, Sandy, Friedman, Karen A., Sunday, Suzanne, Chaudhry, Basit, DiMisa, Deborah, and Fornari, Alice
- Published
- 2013
- Full Text
- View/download PDF
36. The use of quasi-experimental design methods to evaluate and improve the impact of acute care centers on oncologic emergencies.
- Author
-
Sweetenham, John W., primary, Chaudhry, Basit Iqbal, additional, Teng, Benjamin, additional, Yue, Andrew, additional, and Connor, Nora, additional
- Published
- 2021
- Full Text
- View/download PDF
37. Bundling cancer subtypes in value-based care: A pilot analysis of lymphoma episodes in the Oncology Care Model.
- Author
-
Yue, Andrew, primary, Chaudhry, Basit Iqbal, additional, Schleicher, Stephen Matthew, additional, Huntington, Scott F., additional, Lyss, Aaron J., additional, Connor, Nora, additional, Tran, Lisa, additional, and Adelson, Kerin B., additional
- Published
- 2021
- Full Text
- View/download PDF
38. Practice transformation at scale through a microsystems quality improvement (QI) approach.
- Author
-
Gordan, Lucio N., primary, Chaudhry, Basit Iqbal, additional, Hussein, Maen A., additional, Connor, Nora, additional, Yue, Andrew, additional, Diaz, Michael, additional, Strickland, T. R., additional, Tran, Lisa, additional, and Walcker, Nathan, additional
- Published
- 2021
- Full Text
- View/download PDF
39. Evaluating differential cost growth across individual cancers: Insights from Oncology Care Model data.
- Author
-
Chaudhry, Basit Iqbal, primary, Gordan, Lucio N., additional, Yue, Andrew, additional, Tran, Lisa, additional, and Connor, Nora, additional
- Published
- 2021
- Full Text
- View/download PDF
40. New drug approvals and their effect on performance for participants in the Oncology Care Model.
- Author
-
Bilbrey, Larry Edward, primary, Schleicher, Stephen Matthew, additional, Chaudhry, Basit Iqbal, additional, Yue, Andrew, additional, and Blakely, L. Johnetta, additional
- Published
- 2021
- Full Text
- View/download PDF
41. Modeling Medicare’s Oncology Care Model bundles at more clinically granular levels: Evaluating the impact on provider performance.
- Author
-
Yue, Andrew, primary, Connor, Nora, additional, Gordan, Lucio N., additional, Tran, Lisa, additional, and Chaudhry, Basit Iqbal, additional
- Published
- 2021
- Full Text
- View/download PDF
42. Impact of cancer- and patient-level factors on provider risk in the Oncology Care Model.
- Author
-
Chaudhry, Basit Iqbal, primary, Yue, Andrew, additional, Kaila, Shuchita, additional, Sadik, Kay, additional, Tran, Lisa, additional, and Connor, Nora, additional
- Published
- 2021
- Full Text
- View/download PDF
43. Impact of clinical trial enrollment on episode costs in the Oncology Care Model (OCM).
- Author
-
Young, Garrett, primary, Bilbrey, Larry Edward, additional, Arrowsmith, Edward, additional, Blakely, L. Johnetta, additional, Daniel, Davey B., additional, Yue, Andrew, additional, Chaudhry, Basit Iqbal, additional, Spigel, David R., additional, Lyss, Aaron J., additional, Dickson, Natalie R., additional, Fox, John, additional, Schleicher, Stephen Matthew, additional, and Schwartzberg, Lee S., additional
- Published
- 2021
- Full Text
- View/download PDF
44. sj-pdf-1-cep-10.1177_0333102420921855 - Supplemental material for Dizziness and vertigo during the prodromal phase and headache phase of migraine: A systematic review and meta-analysis
- Author
-
Iljazi, Afrim, Ashina, Håkan, Lipton, Richard B, Chaudhry, Basit, Al-Khazali, Haidar M, Naples, James G, Schytz, Henrik W, Cvetkovic, Vlasta Vukovic, Burstein, Rami, and Ashina, Sait
- Subjects
FOS: Psychology ,FOS: Clinical medicine ,170199 Psychology not elsewhere classified ,110319 Psychiatry (incl. Psychotherapy) ,110306 Endocrinology ,111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified ,110904 Neurology and Neuromuscular Diseases ,Neuroscience - Abstract
Supplemental material, sj-pdf-1-cep-10.1177_0333102420921855 for Dizziness and vertigo during the prodromal phase and headache phase of migraine: A systematic review and meta-analysis by Afrim Iljazi, Håkan Ashina, Richard B Lipton, Basit Chaudhry, Haidar M Al-Khazali, James G Naples, Henrik W Schytz, Vlasta Vukovic Cvetkovic, Rami Burstein and Sait Ashina in Cephalalgia
- Published
- 2020
- Full Text
- View/download PDF
45. Two-hour infusion of vasoactive intestinal polypeptide induces delayed headache and extracranial vasodilation in healthy volunteers
- Author
-
Pellesi, Lanfranco, Al-Karagholi, Mohammad Al Mahdi, Chaudhry, Basit Ali, Lopez, Cristina Lopez, Snellman, Josefin, Hannibal, Jens, Amin, Faisal Mohammad, Ashina, Messoud, Pellesi, Lanfranco, Al-Karagholi, Mohammad Al Mahdi, Chaudhry, Basit Ali, Lopez, Cristina Lopez, Snellman, Josefin, Hannibal, Jens, Amin, Faisal Mohammad, and Ashina, Messoud
- Abstract
Background: In recent years, vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptides (PACAPs) have gained special interest in headache science. VIP and PACAPs (two isoforms, PACAP27 and PACAP38) are related in structure and function, as are their receptors, but they show differences in vasodilating- and headache-inducing properties. Intravenous infusion of PACAP27 or PACAP38, but not VIP, induces a long-lasting dilation of cranial arteries and delayed headache. The relationship between the long-lasting cranial vasodilation and headache development is not fully clarified. Methods: In a double-blinded, placebo-controlled, crossover study in 12 healthy volunteers, diameter changes of cranial arteries, occurrence of headache and the parasympathetic system were examined before, during and after a 2-hour continuous intravenous infusion of VIP and placebo. Primary endpoints were the differences in area under the curve for the superficial temporal artery diameter and headache intensity scores, as well as in headache incidence, between VIP and placebo. Results: The superficial temporal artery diameter was significantly larger on the VIP day compared to placebo (p < 0.001) and the dilation lasted for more than 2 h. The incidence of headache was higher (p = 0.003) on the VIP day compared to the placebo day. The difference in headache intensity scores was more evident in the post-infusion period (120–200 min, p = 0.034) and in the post-hospital phase (4–12 h, p = 0.025). Cranial parasympathetic activity, measured through the production of tears, was higher during VIP compared to placebo (p = 0.033). Conclusion: Continuous intravenous infusion of VIP over 2 h induced a long-lasting cranial vasodilation, activation of the cranial parasympathetic system, and delayed mild headaches in healthy volunteers. Trial Registration: The study is registered at ClinicalTrials.gov (NCT03989817).
- Published
- 2020
46. The effect of pituitary adenylate cyclase-activating peptide-38 and vasoactive intestinal peptide in cluster headache
- Author
-
Vollesen, Anne Luise H., Snoer, Agneta, Chaudhry, Basit, Petersen, Anja Sofie, Hagedorn, Andreas, Hoffmann, Jan, Jensen, Rigmor H., Ashina, Messoud, Vollesen, Anne Luise H., Snoer, Agneta, Chaudhry, Basit, Petersen, Anja Sofie, Hagedorn, Andreas, Hoffmann, Jan, Jensen, Rigmor H., and Ashina, Messoud
- Abstract
Background: Previously reported increases in serum levels of vasodilating neuropeptides pituitary adenylate cyclase-activating peptide-38 (PACAP38) and vasoactive intestinal peptide (VIP) during attacks of cluster headache could indicate their involvement in cluster headache attack initiation. We investigated the attack-inducing effects of PACAP38 and vasoactive intestinal peptide in cluster headache, hypothesising that PACAP38, but not vasoactive intestinal peptide, would induce cluster-like attacks in episodic active phase and chronic cluster headache patients. Methods: In a double-blind crossover study, 14 episodic cluster headache patients in active phase, 15 episodic cluster headache patients in remission phase and 15 chronic cluster headache patients were randomly allocated to receive intravenous infusion of PACAP38 (10 pmol/kg/min) or vasoactive intestinal peptide (8 pmol/kg/min) over 20 min on two study days separated by at least 7 days. We recorded headache intensity, incidence of cluster-like attacks, cranial autonomic symptoms and vital signs using a questionnaire (0–90 min). Results: In episodic cluster headache active phase, PACAP38 induced cluster-like attacks in 6/14 patients and vasoactive intestinal peptide induced cluster-like attacks in 5/14 patients (p = 1.000). In chronic cluster headache, PACAP38 and vasoactive intestinal peptide both induced cluster-like attacks in 7/15 patients (p = 0.765). In episodic cluster headache remission phase, neither PACAP38 nor vasoactive intestinal peptide induced cluster-like attacks. Conclusions: Contrary to our hypothesis, attack induction was lower than expected and roughly equal by PACAP38 and vasoactive intestinal peptide in episodic active phase and chronic cluster headache patients, which contradicts the PAC1-receptor as being solely responsible for attack induction. Trial registration: clinicaltrials.gov (identifier NCT03814226).
- Published
- 2020
47. Risk Factors for the Development of Post-Traumatic Headache Attributed to Traumatic Brain Injury:A Systematic Review
- Author
-
Andersen, Amalie M., Ashina, Håkan, Iljazi, Afrim, Al-Khazali, Haidar M., Chaudhry, Basit, Ashina, Messoud, Ashina, Sait, Schytz, Henrik W., Andersen, Amalie M., Ashina, Håkan, Iljazi, Afrim, Al-Khazali, Haidar M., Chaudhry, Basit, Ashina, Messoud, Ashina, Sait, and Schytz, Henrik W.
- Abstract
Objective: To systematically identify risk factors for the development of post-traumatic headache (PTH) attributed to traumatic brain injury (TBI) as defined in the International Classification of Headache Disorders (ICHD). Background: PTH is a common sequela of TBI and a leading cause of injury-related disability worldwide. However, little is known about risk factors for the development of PTH attributed to TBI. Methods: We searched PubMed and Embase for literature on risk factors for the development of acute and/or persistent PTH attributed to TBI in accordance with any version of the ICHD. Original studies published in English and of prospective, cross-sectional or retrospective design were considered for the review. Data extraction was performed independently by 2 investigators. Results: Of 1993 potentially relevant articles identified, 3 articles met the inclusion criteria. The following risk factors were assessed for the development of acute PTH: age, sex, type of injury, loss of consciousness, previous TBIs, history of primary headache disorders, history of chronic pain condition other than headache, current treatment for depression/anxiety, attention or learning disorders, body mass index, and other diseases (not further specified). None of the included studies assessed risk factors for the development of persistent PTH. Conclusions: We found that there is little evidence for any risk factors involved in the development of acute PTH, whereas no study had assessed risk factors for the development of persistent PTH. Further studies are warranted and should be powered to examine possible risk factors for the development of PTH. Rigorous methodology and standardized monitoring should be prioritized to support high-quality research and validate potential findings.
- Published
- 2020
48. Dizziness and vertigo during the prodromal phase and headache phase of migraine:A systematic review and meta-analysis
- Author
-
Iljazi, Afrim, Ashina, Håkan, Lipton, Richard B, Chaudhry, Basit, Al-Khazali, Haidar M, Naples, James G, Schytz, Henrik W, Vukovic Cvetkovic, Vlasta, Burstein, Rami, Ashina, Sait, Iljazi, Afrim, Ashina, Håkan, Lipton, Richard B, Chaudhry, Basit, Al-Khazali, Haidar M, Naples, James G, Schytz, Henrik W, Vukovic Cvetkovic, Vlasta, Burstein, Rami, and Ashina, Sait
- Abstract
OBJECTIVE: To assess the proportion of individuals who report dizziness and/or vertigo during the prodromal phase or headache phase of migraine.METHODS: The databases of MEDLINE and EMBASE were searched for studies on dizziness and/or vertigo during the prodromal phase or headache phase of migraine. Pooled relative frequencies were estimated using a random-effects meta-analysis.RESULTS: We identified nine articles eligible for inclusion. Of these, one study reported results for the prodromal phase, seven studies for the headache phase and one study for both the prodromal and headache phase. In the prodromal phase, 9.0% of individuals with migraine reported dizziness, while 3.3% reported vertigo. During the headache phase, relative frequency of dizziness ranged from 6.7% to 59.6%, while vertigo ranged from 6.4% to 44.7%. The meta-analysis showed a relative frequency of 35.7% for dizziness (95% CI = 13.7-61.5%, I2 = 99%) and 33.9% for vertigo (95% CI = 26.7-41.5%, I2 = 87%). Study quality was rated 5/9 or below for seven studies and 6/9 or above for two studies.CONCLUSION: We found that there is a scarcity of literature on dizziness and vertigo as prodromal- and headache-associated symptoms in individuals with migraine. Methodological variations confound comparisons of epidemiological patterns, although it appears that dizziness and vertigo are more frequent during the headache phase of migraine, compared with the prodromal phase. Future studies should ensure use of standardized definitions and rigorous methodology to enable accurate measurements of dizziness and vertigo in migraine.
- Published
- 2020
49. Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury:an open-label study
- Author
-
Ashina, Håkan, Iljazi, Afrim, Al-Khazali, Haidar Muhsen, Eigenbrodt, Anna Kristina, Larsen, Eigil Lindekilde, Andersen, Amalie Middelboe, Hansen, Kevin John, Braüner, Karoline Bendix, Mørch-Jessen, Thomas, Chaudhry, Basit, Antic, Sonja, Christensen, Casper Emil, Ashina, Messoud, Amin, Faisal Mohammad, Schytz, Henrik Winther, Ashina, Håkan, Iljazi, Afrim, Al-Khazali, Haidar Muhsen, Eigenbrodt, Anna Kristina, Larsen, Eigil Lindekilde, Andersen, Amalie Middelboe, Hansen, Kevin John, Braüner, Karoline Bendix, Mørch-Jessen, Thomas, Chaudhry, Basit, Antic, Sonja, Christensen, Casper Emil, Ashina, Messoud, Amin, Faisal Mohammad, and Schytz, Henrik Winther
- Abstract
Background: Calcitonin gene-related peptide (CGRP) has recently been implicated in the pathogenesis of post-traumatic headache (PTH), which raises the prospect for therapeutic use of monoclonal antibodies targeting CGRP or its receptor. Therefore, we decided to assess the efficacy, tolerability, and safety of erenumab for prevention of persistent PTH attributed to mild traumatic brain injury. Methods: A single-center, non-randomized, single-arm, open-label study of erenumab for adults aged 18-65 years with persistent PTH. Patients were assigned to receive 140-mg erenumab monthly by two subcutaneous 1-mL injections, given every 4 weeks for 12 weeks. The primary outcome measure was the mean change in number of monthly headache days of moderate to severe intensity from baseline (4-week pretreatment period) to week 9 through 12. Tolerability and safety endpoints were adverse events (i.e. number and type). Results: Eighty-nine of 100 patients completed the open-label trial. At baseline, the mean monthly number of headache days of moderate to severe intensity was 15.7. By week 9 through 12, the number was reduced by 2.8 days. The most common adverse events were constipation (n = 30) and injection-site reactions (n = 15). Of 100 patients who received at least one dose of erenumab, two patients discontinued the treatment regimen due to adverse events. Conclusions: Among patients with persistent PTH, erenumab resulted in a lower frequency of moderate to severe headache days in this 12-week open-label trial. In addition, erenumab was well-tolerated as discontinuations due to adverse events were low. Placebo-controlled randomized clinical trials are needed to adequately evaluate the efficacy and safety of erenumab in patients with persistent PTH. Trial registration: ClinicalTrials.Gov, NCT03974360. Registered on April 17, 2019-Retrospectively registered
- Published
- 2020
50. Identity Crisis? Approaches to Patient Identification in a National Health Information Network
- Author
-
Hillestad, Richard, primary, Bigelow, James, primary, Chaudhry, Basit, primary, Dreyer, Paul, primary, Greenberg, Michael, primary, Meili, Robin, primary, Ridgely, M., primary, Rothenberg, Jeff, primary, and Taylor, Roger, primary
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.